Table 4. Risk of breast cancer-specific death according to treatment among non-carriers and BRCA2 carriers (period of diagnosis 1980–2012), multivariatea.
Non-carriers |
BRCA2
mutation |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Patients (n=369) | Deaths (n=71) | HR | 95% CI | P-value | Patients (n=187) | Deaths (n=71) | HR | 95% CI | P-value | P-value interactionb | |
Surgery |
0.007 | ||||||||||
Lumpectomy | 153 | 26 | 1 | 49 | 14 | 1 | |||||
Mastectomy | 214 | 62 | 1.01 | 0.51–2.03 | 0.97 | 138 | 57 | 0.49 | 0.21–1.11 | 0.09 | |
Adjuvant chemotherapy |
0.06 | ||||||||||
None | 185 | 35 | 1 | 82 | 31 | 1 | |||||
Any | 175 | 50 | 0.98 | 0.47–2.04 | 0.96 | 101 | 40 | 0.35 | 0.16–0.80 | 0.01 | |
Anthracyclin | 81 | 15 | 1.41 | 0.54–3.69 | 0.48 | 51 | 15 | 0.36 | 0.13–0.98 | 0.05 | |
Nonanthracyclin | 94 | 35 | 0.84 | 0.38–1.86 | 0.67 | 49 | 24 | 0.34 | 0.14–0.83 | 0.02 | |
Radiation |
0.13 | ||||||||||
None | 167 | 41 | 1 | 86 | 31 | 1 | |||||
Any | 198 | 47 | 0.87 | 0.48–1.56 | 0.64 | 98 | 40 | 1.09 | 0.59–2.04 | 0.78 | |
Adjuvant hormone therapy |
0.16 | ||||||||||
None | 206 | 64 | 1 | 94 | 36 | 1 | |||||
Any | 154 | 22 | 0.65 | 0.32–1.33 | 0.24 | 89 | 35 | 1.03 | 0.41–2.60 | 0.95 |
Abbreviations: CI=confidence interval; HR=hazard ratio.
Model including year of birth, year of diagnosis, size, nodal status, grade, ER status and all other treatment categories.
Interaction between BRCA2 mutation status and the relevant variable.